Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

19.18 +2.15 (+12.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 768,425
Open 17.36
Bid (Size) 18.50 (1)
Ask (Size) 20.00 (5)
Prev. Close 17.03
Today's Range 17.36 - 20.18
52wk Range 11.70 - 58.45
Shares Outstanding 26,418,965
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
4 Analysts Have This to Say About Arcturus Therapeutics
  Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
  
Via Benzinga

Performance

YTD
-51.53%
-51.53%
1 Month
+1.70%
+1.70%
3 Month
+12.96%
+12.96%
6 Month
-23.25%
-23.25%
1 Year
-61.59%
-61.59%

More News

Read More
Recap: Arcturus Therapeutics Q2 Earnings
Via Benzinga
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Expert Ratings for Arcturus Therapeutics
Via Benzinga
Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
93 Biggest Movers From Yesterday
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
70 Biggest Movers From Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Via Benzinga
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics's Earnings Outlook
Via Benzinga
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Via Benzinga
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
28 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
Via Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.